Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amonafide vs Daunorubicin in Secondary AML
NCT00715637Phase 3Unknown
- Sponsor
- Antisoma
- Start
- Jun 2007
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of amonafide in acute myeloid leukemia (AML) (2 arms), sponsored by Antisoma. Primary endpoint: Rate of Complete Remission + Complete Remission with incomplete blood count recovery at Day 67. Status: unknown.
02
Drugs
amonafide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00715637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00715637.